Rutgers Cancer Institute

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm	Not yet recruiting	Phase 2	2026-10-09		NCT07867626
SynKIR-310 for Relapsed/Refractory B-NHL	B-cell neoplasm, Blood Protein Disorders, Digestive System Diseases, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, T-cell/histiocyte rich large B cell lymphoma, Waldenstrom macroglobulinemia, aggressive B-cell non-Hodgkin lymphoma, cardiovascular disorder, diffuse large B-cell lymphoma, digestive system disorder, follicular lymphoma, hematologic disorder, hemorrhagic disease, high grade B-cell lymphoma, histiocytosis, hypertrophic pyloric stenosis, immune system disorder, immunoproliferative disorder, indolent B-cell non-Hodgkin lymphoma, interdigitating dendritic cell sarcoma, large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mantle cell lymphoma, marginal zone lymphoma, monoclonal gammopathy, neoplasm, plasma cell neoplasm, pyloric stenosis, stomach disorder, vascular disorder, vascular hemostatic disease	Recruiting	Phase 1	2026-04-14		NCT06544265

Clinical trials